Wenjing Na
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wenjing Na has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Kai Song
College of Life Sciences, University of Chinese Academy of Sciences , Beijing 100864
2 shared publications- Wei Liang
Protein and Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
2 shared publications - Wenfeng Zeng
National Laboratory of Biomacromolecules, Institute of Biophysics Chinese Academy of Sciences Beijing China
2 shared publications Youwang Wang
College of Life Sciences, University of Chinese Academy of Sciences , Beijing 100864
2 shared publicationsHao Wang
School of Pharmacy Shanghai Jiao Tong University Shanghai 200240 China
1 shared publicationLingtao Jin
Department of Molecular Medicine, University of Texas Health Science Center at San Antonio , TX 78229
1 shared publication
Latest Publications
- Open Access
- 24 June 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (4) , 300-306
PKM2, the “K+ sink” in the tumor interstitial fluid
Wenjing Na, Wenfeng Zeng, Kai Song, Youwang Wang, Luoyang Wang, Ziran Zhao, Lingtao Jin, Ping Zhu, Wei Liang; PKM2, the “K+ sink” in the tumor interstitial
- 24 June 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (4) , 300-306
Open AccessPKM2, the “K+ sink” in the tumor interstitial fluid
Wenjing Na, Wenfeng Zeng, Kai Song, Youwang Wang, Luoyang Wang, Ziran Zhao, Lingtao Jin, Ping Zhu, Wei Liang; PKM2, the “K+ sink” in the tumor interstitial
- Open Access
- 1 November 2023
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (3)
Stable IL‐2 Nano‐Assembly for Improved Anti‐Tumor Effect
Interleukin 2 (IL‐2) is the first approved immune therapeutic drug to treat cancer, however various off‐target effects and intolerable dose‐related toxicities induced by high‐dose intravenous infusion regimens result in a large proportion of patients require dose reduction, preventing the widespread adoption of this treatment. To address these issues, a novel IL‐2 nano‐assembly formulation (nano‐IL‐2) is developed using distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐n‐[methoxy (polyethylene glycol)‐2000] (PEG2000‐DSPE), which is durably stable due to the high binding affinity (10–8 m level) of two components and hardly induces vascular leak or inflamed injury at the injection site. Besides, nano‐IL‐2 exerts excellent solubility, lymph‐targeting property, prolonged and stable serum IL‐2 concentration ranges, and much lower toxicities compared to commercial formulation. Monotherapy of nano‐IL‐2 shows optimal capability to control the growth of murine melanoma and colon cancer. Collectively, the present study provides a novel design strategy for lymph‐targeting IL‐2 formulation which is more suitable for subcutaneous administration with higher safety concern.
- 1 November 2023
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (3)
Open AccessStable IL‐2 Nano‐Assembly for Improved Anti‐Tumor Effect
Interleukin 2 (IL‐2) is the first approved immune therapeutic drug to treat cancer, however various off‐target effects and intolerable dose‐related toxicities induced by high‐dose intravenous infusion regimens result in a large proportion of patients require dose reduction, preventing the widespread adoption of this treatment. To address these issues, a novel IL‐2 nano‐assembly formulation (nano‐IL‐2) is developed using distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐n‐[methoxy (polyethylene glycol)‐2000] (PEG2000‐DSPE), which is durably stable due to the high binding affinity (10–8 m level) of two components and hardly induces vascular leak or inflamed injury at the injection site. Besides, nano‐IL‐2 exerts excellent solubility, lymph‐targeting property, prolonged and stable serum IL‐2 concentration ranges, and much lower toxicities compared to commercial formulation. Monotherapy of nano‐IL‐2 shows optimal capability to control the growth of murine melanoma and colon cancer. Collectively, the present study provides a novel design strategy for lymph‐targeting IL‐2 formulation which is more suitable for subcutaneous administration with higher safety concern.